Join our daily newsletter At The Bell to receive exclusive market insights
- Orthocell (OCC) reports positive results from its crossover patient extension arm of its rotator cuff tendon clinical study
- The results demonstrated OrthoATI is a safe and effective treatment for patients suffering from rotator cuff tendinopathy with intrasubstance tendon tear, compared to the standard of care
- On average, participants in the crossover group experienced almost complete resolution of pain by the sixth month of treatment following dosages of OrthoATI
- Orthocell said the treatment is now well positioned to become the first FDA-approved injectable cell therapy in orthopaedics for the treatment of chronic tendon injuries
- Orthocell is up 2.47 per cent and trading at 41.5 cents nearing market close
Orthocell (OCC) has reported positive results from its crossover patient extension arm of its rotator cuff tendon clinical study.
The study involved patients who suffered from pain and loss of shoulder function for at least six months and had received an average of four failed treatments prior to enrolment treated with OrthoATI or corticosteroid injections.
The clinical study results demonstrated OrthoATI was a safe and effective treatment for patients suffering from rotator cuff tendinopathy with intrasubstance tendon tear, compared directly to the standard of care.
On average, participants in the crossover group experienced almost complete resolution of pain by the sixth month of treatment following dosages of OrthoATI.
Meanwhile, nine out of 11 participants in the study who received corticosteroid treatment in the trial requested treatment with OrthoATI instead, due to a lack of improvement in their shoulder pain or function.
The company said this new additional data support the original randomised controlled rotator cuff study results.
Managing Director Paul Anderson said Orthocell is delighted with the crossover patient study results demonstrating OrthoATI is more effective than steroid injection for treatment of rotator cuff tendinopathy with intrasubstance tendon tear.
“This is an important validation for OrthoATI and the company,” Mr Anderson said.
“We are now in a very strong position to progress our US commercialisation strategy to deliver the first injectable cell therapy in orthopaedics that truly addresses the cause of degeneration and returns patients to full use of their chronically damaged tendons.”
Orthocell said OrthoATI is now well positioned to become the first FDA-approved injectable cell therapy in orthopaedics for the treatment of chronic tendon injuries.
Orthocell was up 2.47 per cent and trading at 41.5 cents nearing market close.
